Latest News

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

Signia Introduces World’s First ‘Face Mask Mode’ for Hearing Devices: Improves Audibility for Those Communicating with Someone Wearing a Face Covering & No More Lip Reading

“The hearing challenges presented by face masks became obvious pretty quickly into the pandemic, so Signia developed the first-of-its-kind Face Mask Mode to help those with hearing loss better communicate in this new reality,” said Tish Ramirez, Au.D. of Signia. “When this setting is activated, the hearing aids optimally capture the sound of the speech signals, enabling the words to sound clearer and reducing any background noise to help the wearer understand what is being said.” 

Modulim Announces CE Mark of Clarifi Imaging System for Microvascular Assessment

Modulim can now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

Genius AI Detection Receives FDA Clearance

Hologic notes the new technology which the company has now made commercially available represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius 3D Mammography exam.

Gregory E. Deavens Honored: Named Chairman of Hartford HealthCare Board

Gregory E. Deavens was named chairman of the Hartford HealthCare Board of Directors on June 16, 2020.

As executive vice president, chief financial officer, and treasurer of Independence Health Group, Gregory E. Deavens is responsible for all financial functions for Independence Health Group and its subsidiaries. He also plays a key role in strategic planning for the organization.

In nominating Deavens, Hartford HealthCare president and chief executive officer Jeffrey A. Flaks praised Deavens as a person of great integrity, a bright and committed leader who has made significant contributions to the financial stability of Hartford HealthCare during his seven years of service as a board member, including prior service as vice chair.

“I have always valued Greg’s expertise, passion and vision and I am excited to partner with him to continue Hartford HealthCare’s growth as the premiere healthcare system in our region,” Flaks said.

“Greg brings strong strategic planning and leadership skills to the role, as well as tremendous vision. He shares my passion for culture, for building a true system-of-care that is a model for the nation. Together, we are committed to building a more diverse and more equitable health system.”

Deavens succeeds David Hess, whose term as chairman ended. Hess will remain a member of the Board of Directors.

“I am honored to accept the very important role as chairman of the Hartford HealthCare Board and I am grateful to David Hess for his leadership and continued support,” Deavens said. “We have an ambitious path ahead of us, as together, we transform health care in Connecticut and beyond, with a clear focus on the Hartford HealthCare mission to improve the health and healing of the people and communities it serves. I am also encouraged by and share Hartford HealthCare’s commitment to eliminating health disparities in underserved communities.”

Before joining Independence Health Group in January 2017, Deavens was senior vice president and corporate controller at MassMutual Financial Group. Previously, he served as senior vice president and chief financial officer for MassMutual’s U.S. Insurance Group. His earlier experience includes financial leadership roles with New York Life Insurance Company, CIGNA, GE Capital, and PriceWaterhouse.

In addition to his leadership on the HHC board, Deavens serves on the board of directors for The Executive Leadership Council, the African American Museum in Philadelphia, and BCS Financial. He is also a member of the American Institute of Certified Public Accountants and the National Association of Corporate Directors.

Deavens holds a Bachelor of Science degree in Accounting from the Florida A&M University School of Business and Industry. He and his wife, Beverly, have three grown children.

Latest Posts

Fusion Antibodies and Queen’s University Belfast Awarded a £453,000 Grant from Invest Northern Ireland

The two organisations will use the funds to accelerate the discovery of novel therapeutic and diagnostic antibodies with validated anti-infective properties against COVID-19. Building on strong scientific knowhow, a new antibody development platform will be created that will help realise the vision of producing a breakthrough therapeutic that directly targets SARS-CoV-2.

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

Signia Introduces World’s First ‘Face Mask Mode’ for Hearing Devices: Improves Audibility for Those Communicating with Someone Wearing a Face Covering & No More Lip Reading

“The hearing challenges presented by face masks became obvious pretty quickly into the pandemic, so Signia developed the first-of-its-kind Face Mask Mode to help those with hearing loss better communicate in this new reality,” said Tish Ramirez, Au.D. of Signia. “When this setting is activated, the hearing aids optimally capture the sound of the speech signals, enabling the words to sound clearer and reducing any background noise to help the wearer understand what is being said.” 

Kayentis, a global provider of digital data capture systems for clinical trials, today announces it has raised €7M (approx. $8.3M) in growth capital.

Kayentis is active in the global electronic Clinical Outcome Assessment (eCOA) market, which is expected to reach $2.6 billion by 2027. Market growth in eCOA – a method of capturing outcomes data electronically in clinical trials – is driven by the clinical trials industry.

Don't Miss

New England Biolabs® Introduces NEBNext® Custom RNA Depletion Design Tool and RNA Depletion Core Reagent Set for Customizable RNA Depletion

This technology has been superb for eliminating the ribosomal RNA for a range of custom projects, including tracking novel viruses in mosquitoes, longitudinal profiling for astronauts, and host-pathogen interactions in COVID samples.

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

"FDA approval of the INTERCEPT Blood System for Cryoprecipitation is an important step forward in our mission to establish pathogen reduction as the standard of care for transfused blood components globally," said William ‘Obi’ Greenman, Cerus’ president and chief executive officer.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials. 

Stoke Therapeutics Announces Proposed Public Offering

November 18, 2020 Stoke Therapeutics, Inc., a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein...